Revisiting Heparin-Induced Thrombocytopenia among Patients Undergoing Free Tissue Transfer: A Systematic Review.
Research article published in Journal of reconstructive microsurgery (2025)
Abstract
Heparin is frequently used to mitigate the risk of thrombosis in microsurgical free tissue transfer. Although rare, heparin-induced thrombocytopenia (HIT) is a severe, life-threatening complication that can arise in patients exposed to heparin products. This systematic review aims to examine patterns in demographics, flap characteristics, diagnostic approaches, and treatment protocols for HIT following free flap reconstruction.A systematic search was conducted across PubMed, MEDLINE, and Web of Science, following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Search terms included "heparin-induced thrombocytopenia," "HIT syndrome," "free flaps," "microsurgery," "plastic surgery," and "reconstructive surgery." Case reports or series written in English that presented patients developing HIT following free flap procedures were included. Eligibility criteria are accessible on the International Prospective Register of Systematic Reviews (PROSPERO; CRD42025650125).A total of 15 articles were included, encompassing a total of 23 free flap reconstruction cases. The median patient age was 52 years, with male predominance (69.6). Lower extremity reconstruction was most common (47.8%), primarily using anterolateral thigh flaps (39.1%). Median 4T score was 6, median time to HIT diagnosis was 6 days, and median nadir platelet count was 72 × 103/μL. Thrombotic complications were common, with venous thrombosis (34.8%) predominating. Argatroban (26.1%) was the most frequently used alternative anticoagulant, while warfarin (30.4%) was the most common discharge medication. Overall flap survival was 43.5%. Meta-analysis revealed no significant difference in flap survival between anticoagulation strategies (95% CI: 0.38-2.63, p = 1.000).HIT represents a rare but devastating complication in free flap reconstruction, with approximately half of the affected flaps failing despite intervention. Although no single anticoagulation strategy demonstrated superior outcomes, expeditious diagnosis and treatment may improve flap salvage rates. This review provides a foundation for developing standardized protocols for HIT management in microsurgical patients.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Heparin is frequently used to mitigate the risk of thrombosis in microsurgical free tissue transfer. Although rare, heparin-induced thrombocytopenia (HIT) is a severe, life-threatening complication that can arise in patients exposed to heparin products.
Warum dies für die Hirudotherapie relevant ist
Dieser systematische Review untersuchte die Heparin-induzierte Thrombozytopenie (HIT) nach mikrochirurgischer freier Gewebetransplantation, identifizierte 23 Fälle aus 15 Artikeln mit einem medianen 4T-Score von 6, einer medianen Zeit bis zur Diagnose von 6 Tagen und einer Gesamtüberlebensrate der Lappen von lediglich 43,5 %. Argatroban (26,1 %) war das am häufigsten verwendete alternative Antikoagulans, während die Metaanalyse keinen signifikanten Unterschied im Lappenüberleben zwischen den Antikoagulationsstrategien ergab. Die Studie besitzt indirekte Relevanz für den Zuständigkeitsbereich der ASH durch den gemeinsamen Kontext der Antikoagulation in der rekonstruktiven Mikrochirurgie, in der die Blutegeltherapie zum Lappen-Salvage eingesetzt werden kann, wobei dieses Abstract jedoch weder Blutegel, Hirudin noch Bivalirudin erwähnt. Einschränkend: Dieser Review konzentriert sich spezifisch auf das HIT-Management und bezieht weder Blutegeltherapie noch aus Blutegeln gewonnene Verbindungen ein; die geringe Fallzahl begrenzt die Generalisierbarkeit.
Zitation
Revisiting Heparin-Induced Thrombocytopenia among Patients Undergoing Free Tissue Transfer: A Systematic Review.
Yamin et al. · Journal of reconstructive microsurgery, 2025
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026